Annual EBITDA:
-$178.85M+$79.39M(+30.74%)Summary
- As of today, ALNY annual EBITDA is -$178.85 million, with the most recent change of +$79.39 million (+30.74%) on December 31, 2024.
- During the last 3 years, ALNY annual EBITDA has risen by +$440.58 million (+71.13%).
- ALNY annual EBITDA is now -4172.50% below its all-time high of -$4.19 million, reached on December 31, 2002.
Performance
ALNY EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly EBITDA:
$18.83M+$7.38M(+64.40%)Summary
- As of today, ALNY quarterly EBITDA is $18.83 million, with the most recent change of +$7.38 million (+64.40%) on June 30, 2025.
- Over the past year, ALNY quarterly EBITDA has dropped by -$18.26 million (-49.23%).
- ALNY quarterly EBITDA is now -90.82% below its all-time high of $205.17 million, reached on September 30, 2023.
Performance
ALNY Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
-$150.29M-$18.26M(-13.83%)Summary
- As of today, ALNY TTM EBITDA is -$150.29 million, with the most recent change of -$18.26 million (-13.83%) on June 30, 2025.
- Over the past year, ALNY TTM EBITDA has dropped by -$271.38 million (-224.11%).
- ALNY TTM EBITDA is now -224.11% below its all-time high of $121.09 million, reached on June 30, 2024.
Performance
ALNY TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
ALNY EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1Y1 Year | +30.7% | -49.2% | -224.1% |
| 3Y3 Years | +71.1% | +108.9% | +79.5% |
| 5Y5 Years | +78.5% | +114.2% | +80.3% |
ALNY EBITDA Highs & Lows
| PeriodPeriod | Annual vs HighAnnual vs High | Annual vs LowAnnual vs Low | Quarter. vs HighQuarter. vs High | Quarter. vs LowQuarter. vs Low | TTM vs HighTTM vs High | TTM vs LowTTM vs Low | |
|---|---|---|---|---|---|---|---|
| 3Y | 3-Year | at high | +80.7% | -90.8% | +105.5% | -224.1% | +83.9% |
| 5Y | 5-Year | at high | +80.7% | -90.8% | +105.5% | -224.1% | +83.9% |
| All-Time | All-Time | -4172.5% | +80.7% | -90.8% | +105.5% | -224.1% | +83.9% |
ALNY EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2025 | - | $18.83M(+64.4%) | -$150.29M(-13.8%) |
| Mar 2025 | - | $11.46M(+107.4%) | -$132.03M(+16.6%) |
| Dec 2024 | -$178.85M(+30.7%) | -$154.99M(-505.6%) | -$158.30M(-44.4%) |
| Sep 2024 | - | -$25.59M(-169.0%) | -$109.66M(-190.6%) |
| Jun 2024 | - | $37.09M(+350.3%) | $121.09M(+188.6%) |
| Mar 2024 | - | -$14.82M(+86.1%) | -$136.73M(+42.8%) |
| Dec 2023 | -$258.24M(+72.1%) | -$106.35M(-151.8%) | -$239.24M(+22.8%) |
| Sep 2023 | - | $205.17M(+193.0%) | -$310.00M(+63.9%) |
| Jun 2023 | - | -$220.73M(-88.1%) | -$859.37M(-1.0%) |
| Mar 2023 | - | -$117.33M(+33.8%) | -$850.47M(+6.6%) |
| Dec 2022 | -$926.56M(-49.6%) | -$177.11M(+48.5%) | -$910.36M(+2.7%) |
| Sep 2022 | - | -$344.21M(-62.5%) | -$935.29M(-27.8%) |
| Jun 2022 | - | -$211.83M(-19.5%) | -$731.82M(-13.9%) |
| Mar 2022 | - | -$177.22M(+12.3%) | -$642.49M(-3.7%) |
| Dec 2021 | -$619.43M(+11.1%) | -$202.03M(-43.5%) | -$619.43M(-1.3%) |
| Sep 2021 | - | -$140.74M(-14.9%) | -$611.60M(+9.5%) |
| Jun 2021 | - | -$122.49M(+20.5%) | -$675.80M(+1.5%) |
| Mar 2021 | - | -$154.16M(+20.6%) | -$686.19M(+1.5%) |
| Dec 2020 | -$696.67M(+16.2%) | -$194.20M(+5.2%) | -$696.67M(+8.8%) |
| Sep 2020 | - | -$204.95M(-54.2%) | -$764.29M(-1.2%) |
| Jun 2020 | - | -$132.88M(+19.3%) | -$754.94M(+8.9%) |
| Mar 2020 | - | -$164.64M(+37.1%) | -$828.40M(+1.2%) |
| Dec 2019 | -$830.88M(-11.5%) | -$261.82M(-33.9%) | -$838.45M(-14.3%) |
| Sep 2019 | - | -$195.60M(+5.2%) | -$733.56M(+7.4%) |
| Jun 2019 | - | -$206.34M(-18.1%) | -$792.12M(-2.1%) |
| Mar 2019 | - | -$174.69M(-11.3%) | -$775.89M(-4.1%) |
| Dec 2018 | -$745.43M(-52.7%) | -$156.93M(+38.3%) | -$745.43M(-1.6%) |
| Sep 2018 | - | -$254.15M(-33.7%) | -$733.55M(-21.9%) |
| Jun 2018 | - | -$190.12M(-31.8%) | -$601.61M(-13.7%) |
| Mar 2018 | - | -$144.23M(+0.6%) | -$528.91M(-8.3%) |
| Dec 2017 | -$488.19M(-19.2%) | -$145.06M(-18.7%) | -$488.19M(-7.2%) |
| Sep 2017 | - | -$122.21M(-4.1%) | -$455.55M(-4.4%) |
| Jun 2017 | - | -$117.41M(-13.4%) | -$436.51M(-7.1%) |
| Mar 2017 | - | -$103.51M(+7.9%) | -$407.54M(+0.5%) |
| Dec 2016 | -$409.46M(-47.8%) | -$112.42M(-9.0%) | -$409.46M(-6.5%) |
| Sep 2016 | - | -$103.18M(-16.7%) | -$384.49M(-8.5%) |
| Jun 2016 | - | -$88.44M(+16.1%) | -$354.37M(-6.1%) |
| Mar 2016 | - | -$105.43M(-20.6%) | -$333.85M(-20.5%) |
| Dec 2015 | -$276.96M(-60.8%) | -$87.44M(-19.7%) | -$276.96M(-19.4%) |
| Sep 2015 | - | -$73.06M(-7.6%) | -$231.89M(-15.4%) |
| Jun 2015 | - | -$67.92M(-40.0%) | -$200.91M(-12.2%) |
| Mar 2015 | - | -$48.53M(-14.5%) | -$179.01M(-3.9%) |
| Dec 2014 | -$172.29M | -$42.37M(-0.7%) | -$172.29M(-9.8%) |
| Sep 2014 | - | -$42.08M(+8.6%) | -$156.88M(-8.7%) |
| Jun 2014 | - | -$46.03M(-10.1%) | -$144.27M(-23.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2014 | - | -$41.81M(-55.0%) | -$116.84M(-41.3%) |
| Dec 2013 | -$82.71M(-51.7%) | -$26.96M(+8.5%) | -$82.71M(-7.3%) |
| Sep 2013 | - | -$29.47M(-58.4%) | -$77.08M(-21.4%) |
| Jun 2013 | - | -$18.60M(-142.3%) | -$63.47M(-16.8%) |
| Mar 2013 | - | -$7.68M(+64.0%) | -$54.33M(+0.4%) |
| Dec 2012 | -$54.53M(-9.7%) | -$21.33M(-34.5%) | -$54.53M(-19.7%) |
| Sep 2012 | - | -$15.86M(-67.6%) | -$45.55M(-11.5%) |
| Jun 2012 | - | -$9.46M(-20.1%) | -$40.87M(+5.5%) |
| Mar 2012 | - | -$7.88M(+36.2%) | -$43.23M(+13.0%) |
| Dec 2011 | -$49.69M(-28.1%) | -$12.35M(-10.5%) | -$49.69M(-3.2%) |
| Sep 2011 | - | -$11.18M(+5.5%) | -$48.13M(-8.4%) |
| Jun 2011 | - | -$11.83M(+17.5%) | -$44.42M(-3.3%) |
| Mar 2011 | - | -$14.34M(-32.9%) | -$42.99M(-10.8%) |
| Dec 2010 | -$38.80M(+5.4%) | -$10.79M(-44.6%) | -$38.80M(-14.7%) |
| Sep 2010 | - | -$7.46M(+28.3%) | -$33.84M(+3.1%) |
| Jun 2010 | - | -$10.40M(-2.5%) | -$34.92M(+22.4%) |
| Mar 2010 | - | -$10.14M(-74.0%) | -$44.98M(-9.7%) |
| Dec 2009 | -$41.02M(-116.6%) | -$5.83M(+31.7%) | -$41.02M(-7.9%) |
| Sep 2009 | - | -$8.54M(+58.3%) | -$38.02M(-22.3%) |
| Jun 2009 | - | -$20.47M(-231.3%) | -$31.09M(-40.6%) |
| Mar 2009 | - | -$6.18M(-117.7%) | -$22.10M(-16.8%) |
| Dec 2008 | -$18.93M(+74.8%) | -$2.84M(-77.0%) | -$18.93M(-368.0%) |
| Sep 2008 | - | -$1.60M(+86.0%) | -$4.04M(+92.3%) |
| Jun 2008 | - | -$11.48M(-282.1%) | -$52.73M(+4.6%) |
| Mar 2008 | - | -$3.01M(-124.9%) | -$55.26M(+26.4%) |
| Dec 2007 | -$75.06M(-110.3%) | $12.05M(+124.0%) | -$75.06M(+21.8%) |
| Sep 2007 | - | -$50.29M(-258.8%) | -$96.01M(-83.0%) |
| Jun 2007 | - | -$14.02M(+38.5%) | -$52.47M(-6.1%) |
| Mar 2007 | - | -$22.80M(-156.1%) | -$49.48M(-38.6%) |
| Dec 2006 | -$35.69M(+11.6%) | -$8.90M(-31.9%) | -$35.69M(+12.8%) |
| Sep 2006 | - | -$6.75M(+38.7%) | -$40.95M(+7.2%) |
| Jun 2006 | - | -$11.02M(-22.3%) | -$44.12M(-1.8%) |
| Mar 2006 | - | -$9.01M(+36.4%) | -$43.35M(-7.4%) |
| Dec 2005 | -$40.35M(-35.3%) | -$14.16M(-42.6%) | -$40.35M(-30.3%) |
| Sep 2005 | - | -$9.93M(+3.1%) | -$30.97M(-15.8%) |
| Jun 2005 | - | -$10.25M(-70.7%) | -$26.74M(-16.2%) |
| Mar 2005 | - | -$6.01M(-25.6%) | -$23.00M(+22.9%) |
| Dec 2004 | -$29.82M(-52.1%) | -$4.78M(+16.1%) | -$29.82M(+34.6%) |
| Sep 2004 | - | -$5.70M(+12.6%) | -$45.62M(-14.4%) |
| Jun 2004 | - | -$6.52M(+49.1%) | -$39.88M(-13.5%) |
| Mar 2004 | - | -$12.82M(+37.7%) | -$35.14M(-49.0%) |
| Dec 2003 | -$19.61M(-368.5%) | -$20.58M(>-9900.0%) | -$23.59M(-684.6%) |
| Sep 2003 | - | $44.00K(+102.5%) | -$3.01M(+1.4%) |
| Jun 2003 | - | -$1.78M(-40.9%) | -$3.05M(-140.9%) |
| Mar 2003 | - | -$1.27M | -$1.27M |
| Dec 2002 | -$4.19M | - | - |
FAQ
- What is Alnylam Pharmaceuticals, Inc. annual EBITDA?
- What is the all-time high annual EBITDA for Alnylam Pharmaceuticals, Inc.?
- What is Alnylam Pharmaceuticals, Inc. annual EBITDA year-on-year change?
- What is Alnylam Pharmaceuticals, Inc. quarterly EBITDA?
- What is the all-time high quarterly EBITDA for Alnylam Pharmaceuticals, Inc.?
- What is Alnylam Pharmaceuticals, Inc. quarterly EBITDA year-on-year change?
- What is Alnylam Pharmaceuticals, Inc. TTM EBITDA?
- What is the all-time high TTM EBITDA for Alnylam Pharmaceuticals, Inc.?
- What is Alnylam Pharmaceuticals, Inc. TTM EBITDA year-on-year change?
What is Alnylam Pharmaceuticals, Inc. annual EBITDA?
The current annual EBITDA of ALNY is -$178.85M
What is the all-time high annual EBITDA for Alnylam Pharmaceuticals, Inc.?
Alnylam Pharmaceuticals, Inc. all-time high annual EBITDA is -$4.19M
What is Alnylam Pharmaceuticals, Inc. annual EBITDA year-on-year change?
Over the past year, ALNY annual EBITDA has changed by +$79.39M (+30.74%)
What is Alnylam Pharmaceuticals, Inc. quarterly EBITDA?
The current quarterly EBITDA of ALNY is $18.83M
What is the all-time high quarterly EBITDA for Alnylam Pharmaceuticals, Inc.?
Alnylam Pharmaceuticals, Inc. all-time high quarterly EBITDA is $205.17M
What is Alnylam Pharmaceuticals, Inc. quarterly EBITDA year-on-year change?
Over the past year, ALNY quarterly EBITDA has changed by -$18.26M (-49.23%)
What is Alnylam Pharmaceuticals, Inc. TTM EBITDA?
The current TTM EBITDA of ALNY is -$150.29M
What is the all-time high TTM EBITDA for Alnylam Pharmaceuticals, Inc.?
Alnylam Pharmaceuticals, Inc. all-time high TTM EBITDA is $121.09M
What is Alnylam Pharmaceuticals, Inc. TTM EBITDA year-on-year change?
Over the past year, ALNY TTM EBITDA has changed by -$271.38M (-224.11%)